CD63-Mediated SARS-CoV-2 RBD Fusion Neoantigen DNA Vaccine Enhances Antitumor Immune Response in a Mouse Panc02 Model via EV-Targeted Delivery
The pCSP vaccine enhances the immunogenicity of neoantigen DNA vaccines by improving EV uptake and immune activation in DCs. These findings provide a potential strategy for improving DNA vaccine efficacy in the context of cancer immunotherapy while maintaining acceptable safety.
Authors
- Ker Yu (ORCID: https://orcid.org/0000-0002-0607-0531)
- Ziyi Wu (ORCID: https://orcid.org/0000-0001-6207-381X)
- Liu Guang (ORCID: https://orcid.org/0000-0002-9958-6077)
- Tingbo Ding
- Qingyuan Yang (ORCID: https://orcid.org/0000-0002-1062-3303)
- Ziqing Yuan
- Jibin Dong (ORCID: https://orcid.org/0000-0002-7969-2622)
Institutions
- Fudan University (CN)
Publication Details
- Journal
- Vaccines
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3390/vaccines13090977
- Citations
- 1
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 1.40